Can we predict who can safely lower Anti-Rejection drugs after hand or face transplants?
NCT ID NCT02055521
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked for immune tolerance markers in 18 hand and face transplant recipients (transplanted at least one year prior). Researchers analyzed blood and skin biopsies to find a 'tolerance signature' that might identify patients who could safely reduce their lifelong anti-rejection medication. The goal is to minimize drug side effects while preventing graft rejection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which transplant recipients can safely lower their anti-rejection drugs, reducing side effects.
- What could go wrong
- This is a small, observational study (18 people) looking for biological markers, not testing a new treatment. The markers may not reliably predict tolerance in hand or face transplants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAND AND FACE ALLOTRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospices Civils de Lyon
Lyon, 69003, France